Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRON Cronos Group	$2.60 +1.6%	$2.12	$1.60 ▼ $2.77	$980.58M	1.01	3.09 million shs	2.79 million shs
GUD Knight Therapeutics	C$6.45 +1.3%	C$6.11	C$5.09 ▼ C$6.49	C$652.42M	0.5	64,927 shs	29,418 shs
THCX AXS Cannabis ETF	$16.60	$16.60	$14.90 ▼ $25.40	$141.07M	1.71	15,071 shs	N/A
TLRY Tilray Brands	$1.15 +3.6%	$0.66	$0.35 ▼ $1.95	$1.22B	1.85	76.17 million shs	51.16 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRON Cronos Group	+1.56%	+9.70%	+24.40%	+28.08%	+8.79%
GUD Knight Therapeutics	+1.26%	+3.70%	+5.39%	+11.40%	+11.40%
THCX AXS Cannabis ETF	0.00%	0.00%	0.00%	0.00%	0.00%
TLRY Tilray Brands	+3.60%	+11.65%	+56.23%	+159.95%	-39.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRON Cronos Group	0.739 of 5 stars	0.0	3.0	0.0	0.0	2.0	0.0	1.3
GUD Knight Therapeutics	1.431 of 5 stars	2.7	0.0	0.0	0.0	1.8	1.7	0.6
THCX AXS Cannabis ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	2.4357 of 5 stars	3.1	1.0	0.0	0.0	3.2	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRON Cronos Group	0.00	N/A	N/A	N/A
GUD Knight Therapeutics	3.33	Buy	C$7.15	10.85% Upside
THCX AXS Cannabis ETF	2.57	Moderate Buy	$16.60	N/A
TLRY Tilray Brands	2.20	Hold	$1.92	66.67% Upside

Current Analyst Ratings Breakdown

Latest GUD, THCX, TLRY, and CRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/29/2025	TLRY Tilray Brands	Zelman & Associates Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRON Cronos Group	$117.61M	8.47	$0.00 per share	5,501.59	$2.95 per share	0.88
GUD Knight Therapeutics	C$348.70M	1.87	C$1.68 per share	3.85	C$7.65 per share	0.84
THCX AXS Cannabis ETF	N/A	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	$821.31M	1.54	$0.15 per share	7.68	$1.40 per share	0.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRON Cronos Group	$41.08M	$0.05	52.00	86.67	N/A	14.19%	-3.78%	-3.62%	11/11/2025 (Estimated)
GUD Knight Therapeutics	-C$30.73M	-C$0.30	N/A	∞	N/A	-8.81%	-4.04%	0.51%	N/A
THCX AXS Cannabis ETF	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	-$2.19B	-$2.31	N/A	N/A	N/A	-265.69%	-6.83%	-5.45%	10/9/2025 (Estimated)

Latest GUD, THCX, TLRY, and CRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	CRON Cronos Group	-$0.02	-$0.10	-$0.08	-$0.10	$45.73 million	$33.46 million
7/28/2025	Q4 2025	TLRY Tilray Brands	-$0.03	$0.02	+$0.05	-$1.30	$250.41 million	$224.54 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
GUD Knight Therapeutics	N/A	N/A	N/A	N/A	N/A
THCX AXS Cannabis ETF	$0.72	4.34%	N/A	N/A	N/A
TLRY Tilray Brands	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRON Cronos Group	N/A	24.65	23.53
GUD Knight Therapeutics	7.52	3.36	1.79
THCX AXS Cannabis ETF	N/A	N/A	N/A
TLRY Tilray Brands	0.20	2.46	1.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRON Cronos Group	8.71%
GUD Knight Therapeutics	12.58%
THCX AXS Cannabis ETF	N/A
TLRY Tilray Brands	9.35%

Insider Ownership

Company	Insider Ownership
CRON Cronos Group	7.30%
GUD Knight Therapeutics	45.62%
THCX AXS Cannabis ETF	N/A
TLRY Tilray Brands	0.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRON Cronos Group	450	383.04 million	355.08 million	Optionable
GUD Knight Therapeutics	725	101.15 million	N/A	Not Optionable
THCX AXS Cannabis ETF	N/A	8.50 million	N/A	Not Optionable
TLRY Tilray Brands	2,842	1.10 billion	1.09 billion	Optionable

GUD, THCX, TLRY, and CRON Headlines

Recent News About These Companies

Tilray Brands, Inc. (NASDAQ:TLRY) Given Average Recommendation of "Hold" by Analysts

August 23 at 3:41 AM | marketbeat.com

Tilray Brands (NASDAQ:TLRY) Stock Price Up 3.3% - Here's What Happened

August 22 at 1:46 PM | marketbeat.com

Tilray Brands (NASDAQ:TLRY) Trading Down 3.3% - Time to Sell?

August 21 at 3:37 PM | marketbeat.com

Tilray's High Hopes: The Catalyst Driving Cannabis Stocks

...

August 21 at 2:09 PM | marketbeat.com

Top Cannabis Stocks To Watch Today - August 20th

August 21 at 1:11 PM | marketbeat.com

Unleashing the Spirit of Adventure: Breckenridge Distillery Launches Mountain Shot, a Bold New Mushroom-Infused Elixir

August 21 at 7:00 AM | globenewswire.com

Tilray Brands (NASDAQ:TLRY) Trading Down 7.5% - Time to Sell?

August 20 at 3:05 PM | marketbeat.com

Cannabis Stocks To Follow Today - August 19th

August 20 at 1:01 PM | marketbeat.com

Tilray Shares Blazing: What's Behind the 55% Rally This Month?

...

August 20 at 11:25 AM | marketbeat.com

If You'd Invested $1,000 in Tilray Stock 5 Years Ago, Here's How Much You'd Have Today

August 20 at 7:01 AM | fool.com

Tilray Brands (NASDAQ:TLRY) Shares Up 9.2% - Time to Buy?

August 19, 2025 | marketbeat.com

Promising Cannabis Stocks To Add to Your Watchlist - August 18th

August 19, 2025 | marketbeat.com

Tilray Brands (NASDAQ:TLRY) Shares Gap Up - Here's Why

August 19, 2025 | marketbeat.com

Tilray Brands (NASDAQ TLRY) Rises Amid NASDAQ Composite Market Trends

August 19, 2025 | kalkinemedia.comK

Promising Cannabis Stocks To Add to Your Watchlist - August 17th

August 18, 2025 | marketbeat.com

National Bank of Canada FI Sells 763,247 Shares of Tilray Brands, Inc. $TLRY

August 18, 2025 | marketbeat.com

Tilray Brands (TLRY) Boosts Revenue Mix with New Cannabis, Wellness, and Beverage Products

August 17, 2025 | insidermonkey.com

Cannabis Stocks Worth Watching - August 16th

August 17, 2025 | marketbeat.com

Best Canadian Cannabis Stocks in 2025

August 17, 2025 | marijuanastocks.comM

Tilray Brands (NASDAQ:TLRY) Trading Down 7.2% - Here's What Happened

August 16, 2025 | marketbeat.com

Best Cannabis Stocks To Follow Today - August 15th

August 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GUD, THCX, TLRY, and CRON Company Descriptions

Cronos Group NASDAQ:CRON

$2.60 +0.04 (+1.56%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.61 +0.01 (+0.23%)

As of 08/22/2025 07:57 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Knight Therapeutics TSE:GUD

C$6.45 +0.08 (+1.26%)

As of 08/22/2025 04:00 PM Eastern

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

AXS Cannabis ETF NYSEARCA:THCX

$16.60 0.00 (0.00%)

As of 03/1/2024

The Cannabis ETF (THCX) is an exchange-traded fund that is based on the AXS Cannabis index. The fund tracks an index of legal cannabis companies selected and weighted by market capitalization. The fund primarily holds North American companies but may also invest in other countries. THCX was launched on Jul 9, 2019 and is managed by AXS Investments.

Tilray Brands NASDAQ:TLRY

$1.15 +0.04 (+3.60%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.14 0.00 (-0.43%)

As of 08/22/2025 07:59 PM Eastern

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time